Medical - Devices
Compare Stocks
2 / 10Stock Comparison
SNWV vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
SNWV vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $143M | $80M |
| Revenue (TTM) | $41M | $133M |
| Net Income (TTM) | $-7M | $2M |
| Gross Margin | 77.7% | 62.0% |
| Operating Margin | 16.6% | 4.8% |
| Forward P/E | 17.4x | — |
| Total Debt | $25M | $35M |
| Cash & Equiv. | $10M | $6M |
SNWV vs XTNT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SANUWAVE Health, In… (SNWV) | 100 | 16.1 | -83.9% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.3 | -53.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNWV vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SNWV is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 60.0%, EPS growth 42.3%, 3Y rev CAGR 35.9%
- -20.7% 10Y total return vs XTNT's -97.8%
- 60.0% revenue growth vs XTNT's 28.4%
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.69
- Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
- Beta 0.69, current ratio 2.35x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 60.0% revenue growth vs XTNT's 28.4% | |
| Quality / Margins | 1.3% margin vs SNWV's -17.1% | |
| Stability / Safety | Beta 0.69 vs SNWV's 1.22 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +10.0% vs SNWV's -47.4% | |
| Efficiency (ROA) | 1.8% ROA vs SNWV's -21.7%, ROIC -12.8% vs 159.8% |
SNWV vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SNWV vs XTNT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — SNWV and XTNT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
XTNT is the larger business by revenue, generating $133M annually — 3.2x SNWV's $41M. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to SNWV's -17.1%. On growth, SNWV holds the edge at +22.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $41M | $133M |
| EBITDAEarnings before interest/tax | $8M | $11M |
| Net IncomeAfter-tax profit | -$7M | $2M |
| Free Cash FlowCash after capex | -$784,000 | $5M |
| Gross MarginGross profit ÷ Revenue | +77.7% | +62.0% |
| Operating MarginEBIT ÷ Revenue | +16.6% | +4.8% |
| Net MarginNet income ÷ Revenue | -17.1% | +1.3% |
| FCF MarginFCF ÷ Revenue | -1.9% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.3% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +117.4% | +123.7% |
Valuation Metrics
XTNT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $143M | $80M |
| Enterprise ValueMkt cap + debt − cash | $158M | $109M |
| Trailing P/EPrice ÷ TTM EPS | -2.37x | -4.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.43x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 24.09x | — |
| Price / SalesMarket cap ÷ Revenue | 4.38x | 0.68x |
| Price / BookPrice ÷ Book value/share | — | 1.77x |
| Price / FCFMarket cap ÷ FCF | 72.67x | — |
Profitability & Efficiency
SNWV leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), SNWV scores 7/9 vs XTNT's 2/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +3.8% |
| ROA (TTM)Return on assets | -21.7% | +1.8% |
| ROICReturn on invested capital | +159.8% | -12.8% |
| ROCEReturn on capital employed | — | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 |
| Debt / EquityFinancial leverage | — | 0.82x |
| Net DebtTotal debt minus cash | $15M | $29M |
| Cash & Equiv.Liquid assets | $10M | $6M |
| Total DebtShort + long-term debt | $25M | $35M |
| Interest CoverageEBIT ÷ Interest expense | 0.13x | 1.55x |
Total Returns (Dividends Reinvested)
Evenly matched — SNWV and XTNT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTNT five years ago would be worth $3,393 today (with dividends reinvested), compared to $2,779 for SNWV. Over the past 12 months, XTNT leads with a +10.0% total return vs SNWV's -47.4%. The 3-year compound annual growth rate (CAGR) favors SNWV at 28.8% vs XTNT's -4.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -42.4% | -24.0% |
| 1-Year ReturnPast 12 months | -47.4% | +10.0% |
| 3-Year ReturnCumulative with dividends | +113.5% | -12.3% |
| 5-Year ReturnCumulative with dividends | -72.2% | -66.1% |
| 10-Year ReturnCumulative with dividends | -20.7% | -97.8% |
| CAGR (3Y)Annualised 3-year return | +28.8% | -4.3% |
Risk & Volatility
XTNT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than SNWV's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTNT currently trades 60.0% from its 52-week high vs SNWV's 35.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 0.69x |
| 52-Week HighHighest price in past year | $46.59 | $0.95 |
| 52-Week LowLowest price in past year | $15.36 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +35.7% | +60.0% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 84K | 142K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $54.00 | — |
| # AnalystsCovering analysts | 2 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
XTNT leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). SNWV leads in 1 (Profitability & Efficiency). 2 tied.
SNWV vs XTNT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SNWV or XTNT a better buy right now?
For growth investors, SANUWAVE Health, Inc.
(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SNWV or XTNT?
Over the past 5 years, Xtant Medical Holdings, Inc.
(XTNT) delivered a total return of -66. 1%, compared to -72. 2% for SANUWAVE Health, Inc. (SNWV). Over 10 years, the gap is even starker: SNWV returned -20. 7% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SNWV or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus SANUWAVE Health, Inc. 's 1. 22β — meaning SNWV is approximately 78% more volatile than XTNT relative to the S&P 500.
04Which is growing faster — SNWV or XTNT?
By revenue growth (latest reported year), SANUWAVE Health, Inc.
(SNWV) is pulling ahead at 60. 0% versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SNWV or XTNT?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning -14. 0% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNWV leads at 16. 6% versus -10. 3% for XTNT. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SNWV or XTNT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SNWV or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). Both have compounded well over 10 years (XTNT: -97. 8%, SNWV: -20. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SNWV and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.